SCHEMBL7022907

SCHEMBL7022907

Cc1ccccc1CNc1nccc(-n2cnc3ccccc32)n1

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LCK P06239 6/20 0.70
MKNK1 Q9BUB5 13/20 0.67
MKNK2 Q9HBH9 11/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7027192 0.86 LCK (0.70) LCKMKNK1MKNK2
SCHEMBL7020088 0.86 LCK (0.70) LCKMKNK1MKNK2
SCHEMBL7025386 0.86 LCK (0.70) LCKMKNK1MKNK2
SCHEMBL7020519 0.85 MKNK1 (0.67) LCKMKNK1MKNK2
SCHEMBL7023275 0.85 LCK (0.69) LCKMKNK1MKNK2
SCHEMBL7023913 0.83 LCK (0.82) LCKMKNK1MKNK2
SCHEMBL7020384 0.83 LCK (0.64) LCKMKNK1MKNK2
SCHEMBL7020797 0.83 LCK (0.66) LCKMKNK1MKNK2
SCHEMBL7022617 0.83 LCK (1.00) LCKMKNK1MKNK2
SCHEMBL7020672 0.81 MKNK1 (1.00) LCKMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed